Does reactivity to multiple Borrelia antigens strengthen evidence of immune recognition?

Borrelia serology is most informative when it identifies a prespecified, validated pattern in a clinically plausible setting—not when individual antigen reactions are treated as a diagnosis.

Clinical and diagnostic evidence

• Multiple reactive Borrelia antigens can strengthen evidence of Borrelia-directed immune recognition relative to an isolated band or antigen. In a six-laboratory European study, requiring two of p58, p19, p50, or p56 yielded 89% sensitivity and 99% specificity in that study panel.
• This does not establish active Lyme borreliosis. Antibodies may persist after resolved infection, while cross-reactive responses—particularly IgM—can occur with EBV, CMV, Mycoplasma pneumoniae, and autoimmune disease.
• Validated standard or modified two-tier serology is the appropriate interpretive framework. Sequential testing improves specificity; standalone or nonvalidated antigen patterns have substantially less clear meaning.

Clinical context and timing

• Exposure history determines pretest probability. Where tick exposure or epidemiologic risk is low, a positive serologic finding is more likely to be false positive.
• Symptoms and timing are essential. Typical erythema migrans is a clinical diagnosis, and serology may be negative before antibodies develop. Conversely, antibody positivity without a compatible syndrome does not demonstrate current disease.
• Isolated IgM deserves particular caution because of lower specificity, cross-reactivity, and persistence; it is generally interpreted only within 30 days of symptom onset.

Assay and mechanistic considerations

• Differences in antigen composition and testing algorithms can produce discordant results across assays, especially for IgM. Regional Borrelia species and assay-specific validation criteria also affect performance.
• PCR is supplementary and specimen-dependent: negative blood or CSF PCR lacks sufficient sensitivity to exclude Lyme disease.

Bottom line

• Multi-antigen reactivity is corroborative evidence of immune recognition, but only a validated two-tier result interpreted alongside exposure risk, compatible symptoms, illness duration, and diagnostic criteria can meaningfully support Lyme borreliosis; it alone does not prove active infection.